Dementia and Alzheimer Disease

The director of the Sean M. Healey & AMG Center for ALS outlined the trial, which will evaluate ideal dose level and frequency of the investigational treatment for patients with C9-ALS and C9-FTD.

The executive director of Banner Alzheimer’s Institute discussed the approval of aducanumab and the potential to address unmet needs and gaps in care for patients with Alzheimer disease.

Developed by Wave Life Sciences, the trial of the investigational treatment, WVE-004, seeks to identify ideal dose level and frequency in patients with C9orf72-associated amyotrophic lateral sclerosis and FTD.

The approval of aducanumab and other advancements in Alzheimer disease diagnosis remain at the forefront of discussion; Eric Reiman, MD, spoke on the state of diagnosis and those ongoing conversations.

Here's what is coming soon to NeurologyLive.

Mike Detke, MD, PhD, chief medical officer, Cortexyme, provided context on atuzaginstat’s high ceiling in Alzheimer disease, its regulatory path, and its unique dental substudy.

The executive director of Banner Alzheimer’s Institute discussed the future of blood tests as a biomarker that may help in addressing current challenges, including drug development.

The professor of brain science and director of the Chambers-Grundy Center for Transformative Neuroscience at UNLV spoke to the recently published HARMONY phase 3 study data.

Neurology News Network for the week ending August 7, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending August 6, 2021.

The executive director of Banner Alzheimer’s Institute commented on ongoing research into amyloid plaque-reducing antibody therapies, the approval of aducanumab, and other initiatives with the ability to impact the treatment of Alzheimer disease.

The assistant professor at Cleveland Clinic provided thoughts on the barriers clinicians face when formulating and conducting Alzheimer disease clinical trials with repurposed drugs.

The phase 3 trial of pimavanserin in dementia-related psychosis, HARMONY, was previous halted due to positive efficacy signs at interim analysis. The drug is currently indicated for use in treating Parkinson disease-related psychosis.

The executive director of Banner Alzheimer’s Institute discussed the current state of AD trials, as well as his perspective on ongoing efforts to establish prevention therapies.

Results and safety data from the phase 1/2 study of the therapy for Hunter syndrome/MPS II were presented at MPS 2021, the 18th International Symposium on MPS and Released Diseases, on July 25.

The duo from the Critical Path Institute detailed the thought process behind evaluating the importance of specific biomarkers and their relation to disability progression in Alzheimer disease.

The chief medical officer of Cortexyme discussed the company’s investigational agent atuzaginstat, its mechanism of action, and the findings of the phase 2/3 GAIN trial.

Cummings and colleagues presented appropriate use criteria for the newly approved Biogen/Eisai agent at the 2021 Alzheimer’s Association International Conference.

Investigators analyzed electronic health records from 10,095 participants over a median follow-up period of 31.7 years.

Here's what is coming soon to NeurologyLive.

AC Immune, the company presenting the data at the 2021 AAIC meeting, also recently acquired an a-syn vaccine, Affiris PD01.

Phase 1b study results were presented at AAIC 2021, supporting the need for accelerated clinical development of ACI-24 in Alzheimer disease related to DS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 30, 2021.

Clive Ballard, MD, spoke on the safety data of pimavanserin, which was presented at the 2021 AAIC meeting, held from July 26-30.

The assistant professor at Cleveland Clinic discussed key factors to consider when choosing repurposed drugs that could show max potential in treating Alzheimer disease.

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jessica Zwerling, MD, MS.

The ICARE AD-US trial is expected to enroll 6000 participants, with at least 16% of the population aimed at including those from underrepresented communities. The unrelated confirmatory phase 4 trial is still in the process of being designed.

Clive Ballard, MD, professor of age related diseases at University of Exeter, commented on the potential impact that the approval of pimavanserin would have for patients if approved for dementia-related psychosis.

The effect of methylphenidate on Alzheimer disease apathy was observed at 2 months and was sustained throughout the 6 months of the study.